Nippon Chemiphar Co., Ltd. (4539)

Overview

Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a prominent entity in the pharmaceutical industry, focusing on the manufacturing, selling, importing, and exporting of ethical pharmaceuticals and diagnostic agents both within Japan and on an international scale. The company, originally established in 1950 and known as Hitachi Chemical Co., Ltd. before its name change in 1970, has its headquarters in Tokyo, Japan. It is dedicated to contributing to healthcare through a diversified portfolio of products and an intensive research and development program aimed at introducing innovative therapeutic options.

Products and Services

Nippon Chemiphar Co., Ltd. offers a wide range of healthcare products and services, which include:

• Diagnostic Products:

  The company provides IgE NC, a diagnostic kit that measures total IgE levels and offers 57 individual allergen reagents for comprehensive allergy testing. Another product, DP3000, is a sophisticated device designed for the measurement of allergen-specific IgE, facilitating accurate allergy diagnosis.

• Pharmaceutical Development:

  Nippon Chemiphar is actively working on several pharmaceuticals currently in various development stages, including:

  • NC-2400: A PPAR-delta agonist under phase 1 development for future therapeutic use.
  • NC-2500: A xanthine oxidase (XOR) inhibitor aimed at treating hyperuricemia/gout, also in phase 1 development.
  • NC-2600: A P2X4 receptor antagonist for the treatment of neuropathic pain, under phase 1 development.
  • NC-2700: A URAT1 inhibitor for treating hyperuricemia and gout, currently in preclinical development.
  • NC-2800: A delta opioid receptor agonist under phase 1 development targeted at depression/anxiety treatment.
  • DFP-17729: A cancer microenvironment improving agent for pancreatic cancer, now in phase 2 development.
  • DE-P-14323: An anti-cancer agent for the treatment of non-small cell lung cancer, under phase 2 development.
• Therapeutic Products:

  The company is also developing therapeutic products such as Soleton, an analgesic and anti-inflammatory drug, and Calvan, a novel treatment for Huntington's disease, both of which are currently under phase 2 development.

• Additional Products:

  In addition to pharmaceuticals and diagnostics, Nippon Chemiphar provides quasi-drugs, nutrients, health foods, cosmetics, and various types of creams, catering to a broad range of health and wellness needs.